Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

A preprint study posted late last week on the server medRxiv reveals that the current Moderna COVID-19 vaccine is 53% ...

However, in the later stages of the pandemic, demand for the product declined, and Moderna shifted to a loss. For example, ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new pandemic surged around them. By a year later, 66 million American adults had ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

COVID-19 vaccination during pregnancy was not associated with major structural birth defects, according to a study published ...

The Kansas Supreme Court is weighing whether to block a sweeping state law that lets workers easily bypass COVID-19 vaccine ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and ...

March 5, 2025 Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on ...